Results of myocardial revascularization in patients with acute coronary syndrome and COVID-19: experience of the urban multidisciplinary hospital

Abstract

Background. The 2019 novel coronavirus pandemic has had a significant impact on the prognosis and outcomes of patients with acute coronary syndrome (ACS).Objective. Study of the impact of a new coronavirus infection (NCI) on the nature of the course and outcomes of the disease in patients with ACS.Materials and methods. The study included patients with ACS and a positive test for COVID-19 upon admission to the hospital in the period from April 2020 to August 2021.Results. The study included 107 patients. Among patients with and without ST elevation with more than 50 % lesions (n = 10; n = 10), 8 patients died, which was 80 % in each group. In the group with and without ST elevation with less than 50 % involvement (n = 20; n = 67), 5 and 8 patients died, accounting for 25 % and 11.9 %, respectively. The role of the influence of the levels of Il-6 (interleukin-6), troponin T and creatinine on the course and outcomes of the patients’ disease was analyzed.Conclusion. COVID-19 infection, namely the degree of damage to the lung tissue, significantly worsens the course and outcomes in patients with both NSTE-ACS and STE-ACS. Further accumulation of clinical experience in endovascular treatment of ACS and the development of algorithms for providing medical care to patients with ACS in the context of COVID-19 is required.